

This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.

The data included in this report reflect the results of a systematic search and review of data on a range of indicators reflecting the extent of services provided to people who inject drugs.

These data have been searched, reviewed and extracted according to decision rules developed by the Reference Group.

Some data have been adjusted to facilitate estimates of standard indicators across countries.

Details of the process for searching, grading and including data, along with their interpretation, are detailed in:

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage. *The Lancet* 2010. DOI:10.1016/S0140-6736(10)60232-2.

For more information on the Reference Group, please go to:
www.IDURefGroup.Com

Section	Page
Estimated number of people who inject drugs and number of injectors who are living with HIV	4
1. Needle and syringe programs (NSPs)	5
NSP 1: Availability of NSPs	
NSP 2: Number of NSP sites	
NSP 3: Number of pharmacy sites where needles and syringes are available for purchase	
NSP 4: Total number of sites where needles and syringes are available	
NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period	
NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period	
NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period	
2. Opioid substitution programs (OST)	10
OST 1: Availability of opioid substitution treatment (OST)	
OST 2: Availability of methadone maintenance treatment (MMT)	
OST 3: Availability of buprenorphine maintenance treatment (BMT)	
OST 4: Availability of other forms of agonist OST	
OST 5: Dose and duration of MMT	
OST 6: Dose and duration of BMT	
OST 7: Total number of all sites providing OST	
OST 8: Number of sites providing MMT	
OST 9: Number of sites providing BMT	
OST 10: Number of sites providing other forms of agonist OST	
OST 11: Number of all clients in any OST at a single point in time	
OST 12: Number of all clients in MMT at a single point in time	
OST 13: Number of all clients in BMT at a single point in time	
OST 14: Number of all clients in other forms of OST at a single point in time	
OST 15: Number of IDUs in any OST at a single point in time	
OST 16: Number of IDUs in MMT at a single point in time	
OST 17: Number of IDUs in BMT at a single point in time	
OST 18: Number of IDUs in other forms of OST at a single point in time	
OST 19: Number of all clients receiving any OST in a 12 month period	
OST 20: Number of all clients receiving MMT in a 12 month period	
OST 21: Number of all clients receiving BMT in a 12 month period	
OST 22: Number of all clients receiving other forms of OST in a 12 month period	
OST 23: Number of IDUs receiving any OST in a 12 month period	
OST 24: Number of IDUs receiving MMT in a 12 month period	

Section	Page
OST 25: Number of IDUs receiving BMT in a 12 month period	
OST 26: Number of IDUs receiving other forms of OST in a 12 month period	
3. Other Drug Treatment (ODT)	24
<hr/>	
ODT 1: Detoxification	
ODT 1.1: Number of sites providing detoxification	
ODT 1.2: Number of IDUs receiving detoxification	
ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time	
ODT 2: Residential Rehabilitation	
ODT 2.1: Number of sites providing residential rehabilitation	
ODT 2.2: Number of IDUs in residential rehabilitation	
ODT 2.3: Number of all clients in residential rehabilitation	
ODT 3: Outpatient psychosocial support, counselling and psychotherapy	
ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy	
ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 4: Peer-based support groups	
ODT 4.1: Number of sites providing peer-based support groups	
ODT 4.2: Number of IDUs in peer-based support groups	
ODT 4.3: Number of all clients in peer-based support groups	
ODT 5: Drug treatment (treatment type not specified)	
ODT 5.1: Number of sites providing unspecified drug treatment	
ODT 5.2: Number of IDUs receiving unspecified drug treatment	
ODT 5.3: Number of all clients receiving unspecified drug treatment	
ODT 6: Drug treatment in prisons	
ODT 6.1: Number of drug treatment sites located in prisons	
ODT 6.2: Number of IDUs receiving drug treatment in prisons	
ODT 6.3: Number of all clients receiving drug treatment in prisons	
ODT 7: Compulsory drug treatment	
ODT 7.1: Number of compulsory detention sites for drug use	
ODT 7.2: Number of IDUs in compulsory detention sites for drug use	
ODT 7.3: Number of all drug users in compulsory detention sites for drug use	
4. HIV testing and counselling (T&C)	39
<hr/>	
T&C 1: Availability of HIV T&C	
T&C 2: Number of sites providing HIV T&C that specifically targets IDUs	

Section	Page
T&C 3: Number of T&C sites providing HIV T& to the general population and also accessible to IDUs	
T&C 4: Number of individual IDUs who were tested for HIV in a 12 month period	
T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result	
5. Anti-retro-viral (ARV) treatment	42
<hr/>	
ARV 1: Number of sites providing ARV treatment	
ARV 2: Number of IDUs receiving ARVs at a single point in time	
ARV 3: Restrictions on IDUs' access to ARVs	
6. Condoms	45
<hr/>	
Condoms 1: Availability of condom programs targeting IDUs	
Condoms 2: Number of sites distributing condoms to IDUs	
Condoms 3: Number of individual IDUs receiving condoms	
Condoms 4: Number of condoms distributed to IDUs	

France (Western Europe)

Estimated number of people who inject drugs and number of injectors who are living with HIV

Estimated prevalence of IDU among general population aged 15-64 years (%)	Low	Mid	High
	0.23	0.32	0.42
Year of IDU prevalence estimate	1999		
Reference for IDU prevalence estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
Estimated prevalence of HIV among people who inject (%)	Low	Mid	High
	6.48	12.2	15.95
Year of HIV prevalence among IDU estimate	2003		
Reference for HIV prevalence among IDU estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age in 2008	40 315 969 (source: UN Population Division, 2009)		
Estimated IDU population in 2008	Low	Mid	High
	94 500	128 500	168 000
Estimated number of IDUs living with HIV in 2008	Low	Mid	High
	6127	15 677	26791

1. Needle and syringe programs (NSPs)

NSP 1: Availability of NSPs

Are NSPs available?	Yes
Comments	
Most recent year of documentation	2007
Reference	See references for other NSP indicators
When were NSPs first introduced?	
Reference	
Are needles and syringes available for purchase from pharmacies?	Yes
Most recent year of documentation	2008
Reference	AVERT. (2008). "Needle exchanges." Retrieved 30 November, 2008, from http://www.avert.org/needle-exchange.htm Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.

NSP 2: Number of NSP sites

Data reported	107 fixed sites, 49 outreach workers sites, 35 mobile sites, 225 vending machines 2014 sites		
Year of reported data	2007 2006		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr . Reitox National Focal Point (2008). France - New developments, trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA. World Health Organization (2009). Universal Access Unpublished Data		
Adjustments	- Assumed counts of all site are mutually exclusive. Total number of sites calculated.		
Final/Adjusted data (to be used as indicator numerator)	416 - 2014		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Number of NSP sites per 1000 IDUs	Low	Mid	High
	2.49	9.49	21.43

NSP 3: Number of pharmacy sites where needles and syringes are available for purchase

Data reported	18000 pharmacies sell needles & syringes A few these do exchange but number not known		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	18 000		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	1999		
General population 15-64 years of age at year of reported data	40 315 969 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Number of pharmacy sites per 1000 IDUs	Low	Mid	High
	107.14	140.08	190.48

NSP 4: Total number of sites where needles and syringes are available

Total number (NSP sites + Pharmacy sites)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data	(source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Total number of sites per 1000 IDUs	Low	Mid	High

NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period

Data reported	Estimated 4000 drug users used specialised harm reduction facilities (CAARUD) during the reporting year, based on 1-week client survey not limited to use of syringe exchange 84 out of 120 agencies reported NSP data		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments	Assumed all clients accessed NSP at some point during 12 month period For lower bound use data only from sites reporting data For upper bound assume rate of access of individual clients is the same across all 120 sites		
Final/Adjusted data (to be used as indicator numerator)	4000 - 5714		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Percentage of IDUs in contact with NSPs in a 12 month period	Low	Mid	High
	2.4	3.8	6.1

NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period

Data reported	NSP present but number of occasions of service not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Number of NSP occasions of service (client contacts) in a 12 month period per IDU	Low	Mid	High
	NK	NK	NK

NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period

Data reported	4800000 syringes provided through needle and syringe programmes 98% of 84 out of 120 agencies that reported NSP data		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments	For lower bound use data from sites reporting only For upper bound assume rate of distribution is constant across all sites and therefore reported figure represents 98% of needle-syringe distribution from 84 agencies Assumed remaining rate of distribution from the remaining 36 agencies is the same as 84 agencies reporting data.		
Final/Adjusted data (to be used as indicator numerator)	4800000 - 6 994 286		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Total number of needles/syringes distributed in a 12 month period per IDU	Low	Mid	High
	28.74	46.1	74.41

NSP: All documents reviewed

Adès, J.-E., E. Janssen, et al. (2007). 2007 national report (2006 data) to the EMCDDA by the Reitox National Focal Point: France. New developments, trends and in-depth information on selected issues. REITOX.

AVERT. (2008). "Needle exchanges." Retrieved 30 November, 2008, from <http://www.avert.org/needle-exchange.htm>

EMCDDA (2007). The State of the Drugs Problem in Europe. Luxembourg: 100.

EMCDDA. (2006). "Number of syringe vending machines and number of syringes distributed or sold in 2002 and 2003." Retrieved 27 January, 2008, from <http://stats06.emcdda.europa.eu/en/elements/nsptab06-en.html>.

Emmanuelli, J. and J.-C. Desenclos (2005). "Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.[see comment][erratum appears in Addiction. 2006 Apr;101(4):616]." Addiction 100(11): 1690-700.

European Monitoring Centre for Drugs and Drug Addiction. (2008). "Health and social responses - Statistical bulletin." Statistical Bulletin Retrieved 6 April 2009, from <http://www.emcdda.europa.eu/stats08/hsr>.

European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from <http://www.emcdda.europa.eu/stats09/hsr>.

International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.

Islam, M. M. and K. Conigrave (2007). "Assessing the role of syringe dispensing machines and mobile van outlets in reaching hard-to-reach and high-risk groups of injecting drug users (IDUs): a review." Harm Reduction Journal 4(1): 14.

Jauffret-Roustide, M., J. Emmanuelli, et al. (2006). "Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data--the ANRS-Coquelicot Study." Substance Use & Misuse 41(10-12): 1603-21.

Prevention Committee (2005). Report on public policy for HIV prevention in Mainland France, Conseil national du sida.

Reitox National Focal Point (2008). France - New developments, trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA,.

WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

2. Opioid substitution treatment (OST)**OST 1: Availability of opioid substitution treatment (OST)**

Are any forms of agonist OST available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was agonist OST first available?	1995
Reference	<p>Jauffret-Roustide, M., J. Emmanuelli, et al. (2006). "Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data--the ANRS-Coquelicot Study." <i>Substance Use & Misuse</i> 41(10-12): 1603-21.</p> <p>European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." <i>Statistical Bulletin</i> 2009, from http://www.emcdda.europa.eu/stats09/hsr.</p>

OST 2: Availability of methadone maintenance treatment (MMT)

Is MMT available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was MMT first available?	1995
Reference	<p>Jauffret-Roustide, M., J. Emmanuelli, et al. (2006). "Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data--the ANRS-Coquelicot Study." <i>Substance Use & Misuse</i> 41(10-12): 1603-21.</p> <p>European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." <i>Statistical Bulletin</i> 2009, from http://www.emcdda.europa.eu/stats09/hsr.</p>

OST 3: Availability of buprenorphine maintenance treatment (BMT)

Is BMT available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was BMT first available?	1996
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." <i>Statistical Bulletin</i> 2009, from http://www.emcdda.europa.eu/stats09/hsr .

OST 4: Availability of other forms of agonist OST

Are other forms of OST available?	Morphine
Comments	
Most recent year of documentation	2009
Reference	World Health Organisation (2009). Global health ATLAS data.
When were other forms of OST first available?	
Reference	

OST 5: Dose and duration of MMT

Average/standard maintenance dose of MMT	70 mg
Comments	
Year	2009
Reference	World Health Organisation (2009). Global health ATLAS data.
Average/standard duration of MMT (range)	
Comments	
Year	
Reference	

OST 6: Dose and duration of BMT

Average/standard maintenance dose of BMT	7 mg
Comments	
Year	2009
Reference	World Health Organisation (2009). Global health ATLAS data.
Average/standard duration of BMT (range)	
Comments	
Year	
Reference	

OST 7: Total number of all sites providing OST

Data reported	19 484 OST sites		
Year of reported data	2006		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	19 484		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	39 949 619 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	93 500	127 000	166 000
INDICATOR: Number of OST sites per 1000 IDUs	Low	Mid	High
	117.37	153.42	208.39

OST 8: Number of sites providing MMT

Data reported	MMT available but number of sites not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Number of MMT sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

OST 9: Number of sites providing BMT

Data reported	BMT available but number not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Number of BMT sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

OST 10: Number of sites providing other forms of agonist OST

Data reported	Other forms of OST available but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 432 713 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Number of sites providing other forms of OST per 1000 IDUs	Low	Mid	High

OST 11: Number of all clients in any OST at a single point in time

Data reported	18 607 - 32000 clients in MMT 83 174 - 97000 clients in BMT [No information on whether number of clients in OST at single point in time (i.e. Census date) or total number of clients receiving OST over a period of time]		
Year of reported data	2007 2009		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr . World Health Organisation (2009). Global health ATLAS data.		
Adjustments	Assumed enrolment at a census date		
Final/Adjusted data (to be used as indicator numerator)	101 781 - 12 9000		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 432 713 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST at census date : 100 IDUs	Low	Mid	High
	60.58	89.80	136.51

OST 12: Number of all clients in MMT at a single point in time

Data reported	18 607 clients in MMT [No information on whether number of clients in MMT at single point in time (i.e. Census date) or total number of clients receiving MMT over a period of time] 30000 on Methadone solution 2000 on Methadone tables		
Year of reported data	2007 2009		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr . World Health Organisation (2009). Global health ATLAS data.		
Adjustments	Assumed count equals enrolment at a census date Figures taken as range		
Final/Adjusted data (to be used as indicator numerator)	18 607 - 32000		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 432 713 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT at census date : 100 IDUs	Low	Mid	High
	11.08	19.69	33.86

OST 13: Number of all clients in BMT at a single point in time

Data reported	83 174 clients in BMT [No information on whether number of clients in BMT at single point in time (i.e. Census date) or total number of clients receiving BMT over a period of time]		
	97000 patients on BMT		
Year of reported data	2007		
	2009		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
	World Health Organisation (2009). Global health ATLAS data.		
Adjustments	Assumed count equals enrolment at a census date		
	Figures taken as a range		
Final/Adjusted data (to be used as indicator numerator)	83 174 - 97000		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
	Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 432 713 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT at census date : 100 IDUs	Low	Mid	High
	49.51	70.11	102.65

OST 14: Number of all clients in other forms of OST at a single point in time

Data reported	Other forms of OST available but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
	Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 432 713 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST at census date : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 15: Number of IDUs in any OST at a single point in time

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Percentage of IDUs in OST at a single point in time	Low	Mid	High
	NK	NK	NK

OST 16: Number of IDUs in MMT at a single point in time

Data reported	MMT available but number of IDUs not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Percentage of IDUs in MMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 17: Number of IDUs in BMT at a single point in time

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Percentage of IDUs in BMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 18: Number of IDUs in other forms of OST at a single point in time

Data reported	Other forms of OST available but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 432 713 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Percentage of IDUs in other forms of OST at a single point in time	Low	Mid	High
	NK	NK	NK

OST 19: Number of all clients receiving any OST in a 12 month period

Data reported	16 807 clients in MMT 83 174 clients in BMT [No information on whether number of clients in OST at single point in time (i.e. Census date) or total number of clients receiving OST over a period of time]		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments	Assumed count equal to total number of clients enrolled in OST throughout 2007		
Final/Adjusted data (to be used as indicator numerator)	101 781		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST in a 12 month period : 100 IDUs	Low	Mid	High
	60.95	79.52	108.28

OST 20: Number of all clients receiving MMT in a 12 month period

Data reported	18 607 clients in MMT [No information on whether number of clients in MMT at single point in time (i.e. Census date) or total number of clients receiving MMT over a period of time]		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments	Assumed count equals total number of clients enrolled in MMT throughout 2007		
Final/Adjusted data (to be used as indicator numerator)	18 607		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT in a 12 month period : 100 IDUs	Low	Mid	High
	11.14	14.54	19.79

OST 21: Number of all clients receiving BMT in a 12 month period

Data reported	83 174 clients in BMT [No information on whether number of clients in BMT at single point in time (i.e. Census date) or total number of clients receiving BMT over a period of time]		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments	Assumed count equals total number of clients enrolled in BMT throughout 2007		
Final/Adjusted data (to be used as indicator numerator)	83 174		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT in a 12 month period : 100 IDUs	Low	Mid	High
	49.80	64.98	88.48

OST 22: Number of all clients receiving other forms of OST in a 12 month period

Data reported	Other forms of OST available but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 432 713 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 23: Number of IDUs receiving any OST in a 12 month period

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Percentage of IDUs receiving OST in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 24: Number of IDUs receiving MMT in a 12 month period

Data reported	MMT available but number of IDUs not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Percentage of IDUs receiving MMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 25: Number of IDUs receiving BMT in a 12 month period

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Percentage of IDUs receiving BMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 26: Number of IDUs receiving other forms of OST in a 12 month period

Data reported	Other forms of OST available but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 432 713 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Percentage of IDUs receiving other forms of OST at a single point in time	Low	Mid	High
	NK	NK	NK

OST: All documents reviewed

Academie nationale de Pharmacie (2009). Bilan des politiques en matiere de substitution aux opiaces.

Adès, J.-E., E. Janssen, et al. (2007). 2007 national report (2006 data) to the EMCDDA by the Reitox National Focal Point: France. New developments, trends and in-depth information on selected issues. REITOX.

AIDES (2002). Réduction des risques Accès aux soins Désir d'enfant Substitution Prévention Hépatites VIH Droits [French].

BISDRO University of Bremen and WIAD Scientific Institute of the German Medical Association Bonn (2008). Reduction of Drug-related Crime in Prison: The impact of opioid substitution treatment on the manageability of opioid dependent prisoners.

Carrieri, M. P. and B. Spire (2008). "Harm reduction and control of HIV in IDUs in France.[comment]." *Lancet* 372(9637): 448.

Carrieri, M. P., L. Amass, et al. (2006). "Buprenorphine use: the international experience." *Clinical Infectious Diseases* 43 Suppl 4: S197-215.

Emmanuelli, J. and J.-C. Desenclos (2005). "Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.[see comment][erratum appears in *Addiction*. 2006 Apr;101(4):616]." *Addiction* 100(11): 1690-700.

European Monitoring Centre for Drugs and Drug Addiction. (2008). "Health and social responses - Statistical bulletin." *Statistical Bulletin* Retrieved 6 April 2009, from <http://www.emcdda.europa.eu/stats08/hsr>.

European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." *Statistical Bulletin* 2009, from <http://www.emcdda.europa.eu/stats09/hsr>.

Gerevich, J., L. Szabo, et al. (2006). "Innovations: Alcohol & Drug Abuse: Methadone Maintenance in Europe and Hungary: Degrees of Sociocultural Resistance." *Psychiatr Serv* 57(6): 776-778.

Hedrich, D., A. Pirona, et al. (2008). "From margin to mainstream: The evolution of harm reduction responses to problem drug use in Europe." *Drugs: education, prevention and policy* 15(6): 503 - 517.

International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.

Jauffret-Roustide, M., J. Emmanuelli, et al. (2006). "Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data--the ANRS-Coquelicot Study." *Substance Use & Misuse* 41(10-12): 1603-21.

Michel, L., M. P. Carrieri, et al. (2008). "Harm reduction and equity of access to care for French prisoners: a review." *Harm Reduction Journal* 5(1):

Reitox National Focal Point (2008). France - New developments, trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA,.

Solberg, U., G. Burkhart, et al. (2002). "An overview of opiate substitution treatment in the European Union and Norway." *International Journal of Drug Policy* 13(6): 477-484.

WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.

World Health Organization (2008). HIV/AIDS care and treatment for people who inject drugs in Asia and the Pacific: an essential practice guide. Geneva, WHO & UNODC: 68.

3. Other drug treatment (ODT)**ODT 1 - Detoxification****ODT 1.1: Number of sites providing detoxification**

Is detoxification available?	Yes		
Number of sites - data reported	Detoxification available but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 432 713 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Number of detoxification sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 1.2: Number of IDUs receiving detoxification

Data reported	Detoxification available but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 432 713 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Percentage of IDUs in detoxification in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in detoxification at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time

Data reported	Detoxification available but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 432 713 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Ratio of number of all clients in detoxification in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all clients in detoxification at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 2 - Residential rehabilitation

ODT 2.1: Number of sites providing residential rehabilitation

Is residential rehabilitation present?			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of residential rehabilitation sites per 1000 IDUs	Low	Mid	High

ODT 2.2: Number of IDUs in residential rehabilitation

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in residential rehabilitation in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in residential rehabilitation at a single point in time	Low	Mid	High

ODT 2.3: Number of all clients in residential rehabilitation

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of number of all drug users in residential rehabilitation in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all drug users in residential rehabilitation at a single point in time : number of IDUs	Low	Mid	High

ODT 3 - Outpatient psychosocial support, counselling and psychotherapy

ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy treatment

Is outpatient psychosocial support, counselling or psychotherapy present?	Yes		
Number of sites - data reported	Psychotherapy, counselling or psychosocial support present but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 432 713 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Number of outpatient psychosocial support, counselling or psychotherapy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychotherapy, counselling or psychosocial support present but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 432 713 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Percentage of IDUs in outpatient psychosocial support, counselling or psychotherapy in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving outpatient psychosocial support, counselling or psychotherapy at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychotherapy, counselling or psychosocial support present but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 432 713 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 4 - Peer-based support groups

ODT 4.1: Number of peer-based support groups sites

Are Peer-based support groups present?	Yes		
Number of sites - data reported	83 NA meetings per week		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments	Assumed each meeting per week occurs at a separate location		
Final/Adjusted data (to be used as indicator numerator)	83		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 315 969 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Number of peer-based support groups sites per 1000 IDUs	Low	Mid	High
	0.49	0.65	0.88

ODT 4.2: Number of IDUs in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 315 969 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Percentage of IDUs in peer-based support groups in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 4.3: Number of all clients in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 315 969 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 500	128 500	168 000
INDICATOR: Ratio of number of all drug users in peer-based support groups in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in peer-based support groups at a single point in time : number of IDUs	Low	Mid	High
	NK	null	null

ODT 5 - Drug treatment (treatment type not specified)

ODT 5.1: Number of drug treatment sites (treatment type not specified)

Type of drug treatment available	In-patient and out-patient treatment - type not specified		
Number of sites - data reported	198 outpatient units 37 inpatient units		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/tdi .		
Adjustments	Assume outpatient and inpatient are situated at different locations and counts of sites are therefore mutually exclusive		
Final/Adjusted data (to be used as indicator numerator)	235		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Number of drug treatment sites per 1000 IDUs	Low	Mid	High
	1.41	1.84	2.50

ODT 5.2: Number of IDUs in drug treatment (treatment type not specified)

Data reported	52 262 clients entering treatment at 120 out of 198 outpatient treatment units reporting data 749 clients entering treatment at 12 out of 37 inpatient treatment units reporting data 10.6% of clients entering treatment injected primary drug		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/tdi .		
Adjustments	For lower bound included data on clients entering treatment only from sites reporting data For upper bound assumed average number clients accessing services per site for sites reporting data is the same as for sites for which data were not reported Number of IDUs in treatment calculated		
Final/Adjusted data for 12 month period (to be used as indicator numerator)	5619 - 9385		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined in a 12 month period	Low	Mid	High
	3.36	6.47	9.98
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 5.3: Number of all clients in drug treatment (treatment type not specified)

Data reported	31 674 clients entering treatment at 120 out of 198 outpatient treatment units reporting data 243 clients entering treatment at 12 out of 37 inpatient treatment units reporting data		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/tdi .		
Adjustments	For lower bound included data on clients entering treatment only from sites reporting data For upper bound assumed average number clients accessing services per site for sites reporting data is the same as for sites for which data were not reported		
Final/Adjusted data for 12 month period (to be used as indicator numerator)	31 917 - 53011		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	40 150 515 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	94 000	128 000	167 000
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined in a 12 month period : number of IDUs	Low	Mid	High
	0.19	0.33	0.56
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 6 - Drug treatment in prisons

ODT 6.1: Number of prison drug treatment sites

Type of drug treatment in prisons?	
Number of sites - data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data	

ODT 6.2: Number of IDUs in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 6.3: Number of all clients in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 7 - Compulsory detention as response to drug use

ODT 7.1: Number of compulsory detention sites for drug use

Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of compulsory detention sites for drug use per 1000 IDUs	Low	Mid	High

ODT 7.2: Number of IDUs in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings at a single point in time	Low	Mid	High

ODT 7.3: Number of all drug users in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings at a single point in time : number of IDUs	Low	Mid	High

ODT: All documents reviewed

Adès, J.-E., E. Janssen, et al. (2007). 2007 national report (2006 data) to the EMCDDA by the Reitox National Focal Point: France. New developments, trends and in-depth information on selected issues. REITOX.

European monitoring Centre for Drugs and Drug Addiction. (2008). "Treatment demand indicator - Statistical bulletin " Statistical Bulletin Retrieved 6 April, 2009, from http://www.emcdda.europa.eu/html.cfm/index65250EN.html?type=stats&stat_category=w100&stat_type=w87&order=stat_reference&CFID=5203606&CFTOKEN=161d43f9a7fd61fb-2D894FE8-E64D-EF3F-72C0BF31D6EAF23A&jsessionid=3830aef6e3d5cdb788212d644b714373741b.

European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from <http://www.emcdda.europa.eu/stats09/tdi>.

Reitox National Focal Point (2008). France - New developments, trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA,.

World Health Organisation (2009). Global health ATLAS data.

4. HIV testing and counselling (T&C)

T&C 1: Availability of HIV T&C

Is T&C available?	Yes
Most recent year of data	2002
Reference	See references for other VCT indicators

T&C 2: Number of sites providing HIV T&C specifically targeting IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Number of targeted T&C sites per 1000 IDUs	Low	Mid	High

T&C 3: Number of sites providing HIV T&C sites to the general population and also accessible to IDUs

Data reported	386 anonymous screening centres (Centres de Dépistage Anonymes et Gratuits, CDAGs)		
Year of reported data	2002		
Reference	Adès, J.-E., E. Janssen, et al. (2007). 2007 national report (2006 data) to the EMCDDA by the Reitox National Focal Point: France. New developments, trends and in-depth information on selected issues. REITOX.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	386		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	38 933 675 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	91 000	124 000	162 000
INDICATOR: Number of all T&C sites per 1000 IDUs	Low	Mid	High
	2.38	3.11	4.24

T&C 4: Number of Individual IDUs who were tested for HIV in 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Percentage of individual IDUs accessing T&Cs in a 12 month period	Low	Mid	High

T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result

Year of reported data	
Reference	
Data reported for both male and female IDUs	
Adjustments	
Final/Adjusted data	
Data reported for male IDUs	
Adjustments	
Final/Adjusted data	
Data reported for female IDUs	
Adjustments	
Final/Adjusted data	

T&C: All documents reviewed

Adès, J.-E., E. Janssen, et al. (2007). 2007 national report (2006 data) to the EMCDDA by the Reitox National Focal Point: France. New developments, trends and in-depth information on selected issues. REITOX.

WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.

5. Anti-retro-viral (ARV) treatment**ARV 1: Number of sites providing ARV treatment**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
HIV among IDU prevalence estimate (%)	Low	Mid	High
Reference			
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator)	Low	Mid	High
INDICATOR: Number of ARV treatment sites per 1000 IDUs	Low	Mid	High
INDICATOR: Number of ARV treatment sites per 1000 IDUs living with HIV	Low	Mid	High

ARV 2: Number of IDUs receiving ARVs at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
HIV among IDU prevalence estimate (%)	Low	Mid	High
Reference			
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of IDUs on ART: 100 IDUs living with HIV	Low	Mid	High

ARV 3: Restrictions on IDUs' access to ARVs

Do restrictions exist which limit IDUs' access to ARV treatment?	
Year of reported data	
Reference	

ARV: All documents reviewed

Michel, L., M. P. Carrieri, et al. (2008). "Harm reduction and equity of access to care for French prisoners: a review." *Harm Reduction Journal* 5(1):

6. Condoms

Condoms 1: Availability of condom programs targeting IDUs

Are condom programs targeting IDUs available?	Yes
Comments	Pharmacy injection kits include condoms
Year	2003
Reference	Emmanuelli, J. and J.-C. Desenclos (2005). "Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.[see comment][erratum appears in Addiction. 2006 Apr;101(4):616]." Addiction 100(11): 1690-700.

Condoms 2: Number of sites distributing condoms to IDUs

Data reported	Condom programs for IDUs present but number not known		
Year of reported data	2003		
Reference	Emmanuelli, J. and J.-C. Desenclos (2005). "Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.[see comment][erratum appears in Addiction. 2006 Apr;101(4):616]." Addiction 100(11): 1690-700.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	39 207 624 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	92 000	125 000	163 000
INDICATOR: Number of condom distribution sites targeting IDU per 1000 IDUs	Low	Mid	High
	NK	NK	NK

Condoms 3: Number of individual IDUs receiving condoms

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving condoms in a 12 month period	Low	Mid	High

Condoms 4: Number of condoms distributed to IDUs

Data reported	Condom programs for IDUs present but number not known		
Year of reported data	2003		
Reference	Emmanuelli, J. and J.-C. Desenclos (2005). "Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.[see comment][erratum appears in Addiction. 2006 Apr;101(4):616]." Addiction 100(11): 1690-700.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.23	0.32	0.42
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	39 207 624 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	92 000	125 000	163 000
INDICATOR: Total number of condoms distributed per 12 month period per IDU	Low	Mid	High
	NK	NK	NK

Condoms: All documents reviewed

Emmanuelli, J. and J.-C. Desenclos (2005). "Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.[see comment][erratum appears in *Addiction*. 2006 Apr;101(4):616]." *Addiction* 100(11): 1690-700.